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Abstract
Background: During untreated, chronic HIV-1 infection, plasma viral load (VL) is a relatively stable quantitative trait that has
clinical and epidemiological implications. Immunogenetic research has established various human genetic factors, especially
human leukocyte antigen (HLA) variants, as independent determinants of VL set-point.
Methodology/Principal Findings: To identify and clarify HLA alleles that are associated with either transient or durable
immune control of HIV-1 infection, we evaluated the relationships of HLA class I and class II alleles with VL among 563
seroprevalent Zambians (SPs) who were seropositive at enrollment and 221 seroconverters (SCs) who became seropositive
during quarterly follow-up visits. After statistical adjustments for non-genetic factors (sex and age), two unfavorable alleles
(A*3601 and DRB1*0102) were independently associated with high VL in SPs (p,0.01) but not in SCs. In contrast, favorable
HLA variants, mainly A*74, B*13, B*57 (or Cw*18), and one HLA-A and HLA-C combination (A*30+Cw*03), dominated in SCs;
their independent associations with low VL were reflected in regression beta estimates that ranged from 20.4760.23 to
20.9260.32 log10 in SCs (p,0.05). Except for Cw*18, all favorable variants had diminishing or vanishing association with VL
in SPs (p#0.86).
Conclusions/Significance: Overall, each of the three HLA class I genes had at least one allele that might contribute to
effective immune control, especially during the early course of HIV-1 infection. These observations can provide a useful
framework for ongoing analyses of viral mutations induced by protective immune responses.
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Introduction
Polymorphic human leukocyte antigen (HLA) molecules
facilitate immune surveillance by presenting a wide spectrum of
self and foreign antigens to T-cells and by serving as ligands for
killer immunoglobulin-like receptors (KIRs) on natural killer (NK)
cells. The extensive HLA allelic diversity [1,2,3,4] reflects positive,
negative, and balancing selections by myriad human pathogens
[5]. In the context of human immunodeficiency virus type 1 (HIV-
1) infection, multiple HLA class I alleles have been shown to
differentially influence viral pathogenesis, often as a result of their
selective targeting of viral epitopes for cytotoxic T-lymphocyte
(CTL) responses [6,7,8]. Such CTL responses frequently and often
rapidly induce viral immune escape, regardless of patient
populations or HIV-1 subtypes (clades) [8,9,10,11,12,13,14]. Viral
adaptation to HLA class I-restricted, protective CTL responses
can even reach fixation in a given population if the resulting viral
mutations have little or no impact on viral fitness [15]. In contrast,
HIV-1 variants with CTL-driven mutations that are associated
with substantial fitness costs can readily revert to the wild-type
once they inhabit individuals who lack the CTL-inducing HLA
alleles or their equivalents [11,16]. Understanding such intrinsic
virus-HLA interplay at both the individual and population levels
should help elucidate correlates of protection against HIV-1
infection, which are critical to the design of effective interventions.
Differential impact of HLA alleles on HIV-1 viral load (VL) was
first observed among seroconverted men in the Multicenter AIDS
Cohort Study [17], shortly after viral load was recognized as a
clinically important outcome [18,19]. More recently, at least three
independent genome-wide association studies have confirmed that
HLA genes are true quantitative trait loci (QTL) related to HIV-1
viremia [20,21,22]. These findings are consistent with other
documented associations of HLA alleles or their supertypes with
rates of HIV-1 disease progression (time to AIDS or CD4
+ T-cell
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been considered as universally favorable or unfavorable.
In our own work, several HLA alleles and haplotypes have been
associated with low (favorable) or high (unfavorable) VL in adult
Zambians predominantly infected with HIV-1 clade C (HIV-1C)
viruses [28]. HLA-B*57 as a universally favorable HLA variant
[29] was further associated with reduced rate (and incidence) of
HIV-1 transmission from seropositive Zambians to their cohab-
iting partners [30]. To refine and expand these observations in our
enlarged Zambian cohort, we have evaluated the potentially
distinctive HLA relationships in seroconverters (SCs) and ser-
oprevalent patients (SPs).
Results
Overall Characteristics of HIV-1 Seropositive Zambians
For this study, 784 HIV-1 seropositive Zambian adults consisted
of 563 SPs who were seropositive at enrollment and 221 SCs who
became seropositive during quarterly follow-up visits (Table 1).
Most of them had the first known seropositive tests between 1996
and 2004. At the time of VL measurements, SPs had a median
duration of follow-up (DOF) of 546 days, while SCs had a median
duration of infection (DOI) of 229 days. DOF was defined as the
time interval from enrollment to first plasma sample used for VL.
DOI was the interval from the estimated time of HIV-1 infection
(the midpoint between last seronegative test and first seropositive
test) to the first plasma taken at least 63 days after infection. Except
for a few outliers, DOF and DOI relative to VL measurements
were ,2,000 and ,600 days, respectively (Figure 1). Neither
DOF nor DOI correlated with log10 VL (p$0.12). Between the
two patient groups, statistically significant (p#0.05) differences
were seen for sex ratio, age, and the distribution of three VL
categories previously shown to be highly predictive of viral
transmission potential [30,31,32]. The minor difference between
SPs and SCs in log10 VL was well within the boundary (0.30 log10)
of biological and epidemiological relevance [19,33]. For consis-
tency with earlier work [28], sex and age group ($40 versus ,40
years) were retained as covariates (non-genetic factors) in
subsequent association models.
HLA Class I Alleles and Their Common Haplotypes in
Zambians
For the 784 HIV-1 seropositive Zambians, molecular genotyp-
ing for the three HLA class I genes (HLA-A, HLA-B, and HLA-C)
resolved most alleles to their 4-digit (high resolution) designations
while leaving some at their 2-digit (allele group) specificities. HLA
class I allele groups with multiple common alleles were limited to
A*02, A*30, A*68, B*14, B*15, B*42, B*44, B*57, B*58, Cw*02,
Cw*03, and Cw*07. The overall frequencies of HLA class I alleles
and haplotypes (local and extended) in the study population were
highly comparable to those seen in 429 discordant couples (858
individuals, including 204 who remained HIV-1 seronegative)
analyzed previously for heterosexual HIV-1 transmission [30].
One striking observation in our population was the high frequency
(17%) of B*1503-Cw*0210 (or B*15-Cw*02), a haplotype rarely
reported elsewhere [34,35,36]. Eight HLA class I alleles (A*11,
A*32, B*27, B*3502, B*3503, B*55, B*56, and Cw*05) reportedly
associated with HIV-1 in populations of European ancestry
[17,22,24,37] were too rare to be assessed in Zambians (number
of subjects ranged from one to 13).
Tests of linkage disequilibrium (LD) among HLA class I alleles
focused on common allele groups seen in at least 16 individuals
(,2% of the study population). A total of 32 common, 2-locus
haplotypes were identified (Table S1). Correlation coefficients (r)
in pairwise LD tests ranged from 0.17 to 0.97 (p,0.001 for all).
Only two pairs of alleles, B*39 with Cw*12 plus B*42 with Cw*17,
were considered as tagging for each other (r
2.0.75, p,1610
216).
Accordingly, the vast majority of individual HLA class I alleles
required independent testing in association analyses. Three
common HLA class I combinations, A*23+B*14, A*23+Cw*07,
and A*30+Cw*03, were also tested selectively because they were
considered as probable haplotypes associated with HIV-1 VL in
Zambians [28].
HLA Class II Alleles and Their Common Haplotypes in
Zambians
Alleles for two HLA class II genes, HLA-DRB1 and HLA-DQB1,
were fully resolved to their 4-digit designations in all but three of
Table 1. Characteristics of 563 Zambians who were HIV-1 seropositive at enrollment and 221 seroconverters who became
seropositive during quarterly follow-up visits.
Characteristics HIV-1 seroprevalents (SPs) Seroconverters (SCs) p
Dates of seropositive tests 08/1999 (10/1996-03/2004) 10/2001 (03/1998-03/2004) NA
DOF or DOI (in days) 546 (252–962) 229 (134–334) ,0.0001
Sex ratio: M/F 288/275 (1.05) 90/131 (0.69) 0.009
Age (yrs, mean 6 SD) 31.067.8 28.867.4 ,0.001
Age group (n, %) 0.064
$40 yrs 108 (19.2) 30 (13.6)
,40 yrs 455 (80.8) 191 (86.4)
Viral load categories (n, %) 0.034
Low (,10
4 copies/mL) 105 (18.7) 51 (23.1)
Medium (10
4–10
5) 232 (41.2) 103 (46.6)
High (.10
5 copies/mL) 226 (40.1) 67 (30.3)
log10 viral load (mean 6 SD) 4.7160.78 4.5460.77 0.006
Dates (month/year) of seropositive tests, duration of follow-up (DOF, for SPs), and duration of infection (DOI, for SCs) are shown as median and interquartile range (in
parentheses). The difference between patient groups is assessed using Mann-Whitney U test. All other comparisons between patient groups are based on Student’s
t-test (for quantitative measures) and x
2 test (for categorical measures). F = female; M = male; NA = not applicable; SD = standard deviation of the mean.
doi:10.1371/journal.pone.0009629.t001
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found in at least 16 individuals qualified for formal association
analyses. Strong linkage disequilibrium (LD) among alleles at these
two neighboring class II loci allowed unambiguous assignment
of 2-locus haplotypes in these subjects (probabilities .95% for all),
leading to the identification of 19 common haplotyes
(r=0.2220.95, p#0.01) (Table S1). Only the neighboring alleles
DRB1*0302 and DQB1*0402 were in sufficient LD to tag each
other (r
2=0.89, p,1610
216). One common haplotype,
DRB1*1301-DQB1*0501, appeared to be unique to the Zambian
population. The frequency of the haplotype DRB1*1101-
DQB1*0602 exceeded that of DRB1*1101-DQB1*0301 in Zam-
bians; that excess has not been reported in other populations of
African ancestry [38]. These overall allele and haplotype fre-
quency patterns were similar to those seen in 584 Zambians
(including 151 HIV-1 seronegatives) analyzed earlier for hetero-
sexual HIV-1 transmission [32].
Analyses Using Categorical and Quantitative VL Measures
We used log10 VL and two contrasting VL categories (high
versus low) as alternative outcome measures in generalized linear
models (GLMs) and logistic regression models to screen the effects
of common HLA alleles and haplotypes, including fully resolved
HLA class I alleles (e.g., A*6801, A*6802, B*3501, B*1302,
B*3910, B*5801, and B*5802) implicated in earlier studies of
native Africans or African-Americans [28,39,40,41,42]. The VL
measure was first evaluated in SPs and SCs combined to improve
statistical power (sample size) [28,35]. The comparison between
the more extreme (categorical) VL outcomes excluded 335 patients
(42.7%) with intermediate VL in order to reduce the potential
misclassification (overlapping) between patient groups [26,43].
In univariate GLMs, eight individual HLA variants and two
HLA-A and HLA-C allele combinations were significantly associ-
ated with HIV-1 VL in this study population (p#0.04) (Table 2).
Five of these variants were favorable and five unfavorable, with the
number of individuals carrying them ranging from 42 (5.4%) to
116 (14.8%). All variants from class I loci have shown similar
associations elsewhere [28,35]. B*57 and Cw*18, which were in
strong LD (r=0.75, p,1610
216), were the most favorable alleles
(mean b estimates #20.34 log10); A*36 and DRB1*0102 were
most unfavorable (mean b close to 0.30 log10 for both). These VL
differences approached and usually exceeded the quantitative
threshold (60.30 log10,o r,2-fold difference) considered biolog-
ically and epidemiologically significant [19,33]. The weak
association for Cw*16 (p=0.08) was explained by its LD
(r=0.57, p,1610
216) with an established unfavorable allele
B*45 (p=0.05).
Despite almost 43% reduction in the total sample size, the
logistic regression models provided confirmatory findings for seven
of 10 HLA variants detected in GLMs (Table 2). The associations
Figure 1. Distribution of HIV-1 viral load (VL) in the study population, with stratification by sex and serostatus at enrollment. There
is no linear correlation between duration of follow-up and log10 VL in seroprevalent Zambians (p$0.12) or duration of infection and log10 VL in
seroconverters (p$0.56). In each panel, the projected slope and its 95% confidence interval are shown in solid and dotted lines, respectively.
doi:10.1371/journal.pone.0009629.g001
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statistically significant (p=0.13, 0.08, and 0.11, respectively).
Among the seven associations supported by logistic regression
models, A*36 and DRB1*0102 were among the most unfavorable,
while Cw*18 and B*57 were among the most favorable. These
seven associations were further confirmed in alternative GLMs,
where the parameter estimates improved for all (Table S2). For
all 10 HLA variants associated with VL using either outcome, their
rankings based on respective beta estimates and on odds ratios had
a strong correlation (Spearman r=0.99, p,0.0001). However, the
same analytic approach failed to confirm the associations of 16
HLA variants with HIV-1 disease control, as previously reported
for populations of European and African ancestry (Table S3).
Stratified Analysis of SPs and SCs
For separate analyses of SPs and SCs, we first assessed the
relationships across three categories of HIV-1 VL. Three alleles
(A*36, A*74, and B*57) showed highly consistent effects on VL in
both SPs and SCs (p#0.02 in univariate Cochran-Armitage trend
test in each patient group) (Table 3). Three associations (B*5802,
Cw*18, and DRB1*0102) were restricted to SPs (p=0.02,
,0.0001, and ,0.01, respectively). Modest LD between A*29
and B*13 (r=0.27) (Table S1) appeared to account for the
association of A*29 in SCs (p=0.05): in the absence of B*13, the
association of A*29 was no longer statistically significant (p=0.09).
Among HLA class I alleles associated with HIV-1 VL in either
SPs or SCs or both groups, A*36 and B*5802 were unfavorable,
while A*29, A*74, B*57, and Cw*18 were favorable; all of these
were consistent with our earlier observations based on a smaller
number of Zambians [28,30,41]. Alleles implicated in other studies
(Table S3) [35,41,42] could not be confirmed in logistic
regression models (Table 3) or alternative models (Table S3).
Only B*57, represented primarily by B*5703 in Zambians, showed
both strong internal consistency (between SPs and SCs) and
unequivocal external corroboration [30,44].
By GLM, including statistical adjustments for the effects of sex
and age on HIV-1 VL, only B*57 (favorable) and B*5802
(unfavorable) were associated with log10 HIV-1 VL in both SPs
and SCs (p#0.05) (Table 4). Six additional associations were seen
only in SPs: unfavorable for A*36, B*45, and DRB1*0102
(p=0.004, 0.010, and 0.002, respectively) and favorable for
B*8101, Cw*18, and A*30+Cw*03 (p=0.025, ,0.0001, and
0.034, respectively). In addition, A*29 and A*74 were favorable
only in SCs (p=0.015 and ,0.001, respectively).
Biologically and epidemiologically meaningful differences (0.30
log10) in VL were observed for only three most favorable HLA
alleles (A*29, A*74, and B*57) in SCs, their regression beta
estimates ranged from 20.4260.17 to 20.6260.20 log10
(Table 4). However, in SPs the respective estimates diminished
by at least 0.30 log10 (a two-fold difference). Although strong LD
between B*57 and Cw*18 (r=0.74 and 0.77 in SPs and SCs,
respectively, p,1610
216 for both) would have predicted similar
impact of these two alleles in both patient groups, the impact of
B*57 appeared stronger in SCs. B*13 (all B*1302 in this cohort)
was clearly favorable in SCs (20.7860.33 log10, p=0.02), but its
effect vanished in SPs (0.0360.16 log10, p=0.86).
The effect sizes of the unfavorable A*36 and B*5802 varied little
between SPs and SCs. For B*45 and DRB1*0102, the unfavorable
effect observed in SPs was absent in SCs (Table 4). Again, the
same analytic approach did not confirm or imply the involvement
of other HLA alleles of major interest (Table S3) [[28,35,41,42].
Multivariable Analyses of HLA Variants and log10 VL
In a reduced multivariable model for SPs, A*36 and
DRB1*0102 continued to show unfavorable association with VL
(+0.25 and +0.38 log10, respectively, p,0.01 for both) (Table 5),
while at least five HLA alleles and one HLA combination were
retained as additional cofactors (adjusted p,0.05 for all) (Table 5).
Based on their respective effect sizes (adjusted beta estimates),
B*57, B*8101, and A*30+Cw*03 had similarly favorable impact
on VL (,20.30 log10), and A*74 showed more modest impact
(20.2060.08 log10). Cw*18 could replace B*57 and B*8101 as an
independent factor (p,0.0001), but the association of B*57 and
B*8101 was no longer statistically significant when the three
variants were forced into the same model (results not shown).
Table 2. List of 11 HLA variants associated with HIV-1 viral load (VL) based on either generalized linear models (Series 1) or logistic
regression analyses (Series 2).
Series 1: all 784 Zambians Series 2: high versus low VL
HLA variants No. of subjects Mean b 6 SE
c p No. of subjects OR (95% CI)
d p
A*36 95 0.2660.08 0.001 54 3.61 (1.66–7.88) 0.001
A*74 108 20.2160.08 0.006 61 0.54 (0.30–0.97) 0.038
B*45
e 106 0.1660.08 0.043 65 1.62 (0.86–3.04) 0.133
B*57 93 20.3460.08 ,0.0001 55 0.31 (0.17–0.58) ,0.001
B*5802 65 0.2160.10 0.031 43 2.01 (0.92–4.38) 0.080
B*81 52 20.3060.11 0.005 35 0.42 (0.20–0.89) 0.024
Cw*16
e 100 0.1460.08 0.079 66 1.66 (0.88–3.14) 0.121
Cw*18 111 20.3760.07 ,0.0001 67 0.26 (0.15–0.47) ,0.0001
DRB1*0102 63 0.2860.10 0.005 38 3.24 (1.34–7.86) 0.009
A*23+Cw*07 56 0.2260.10 0.033 33 2.09 (0.85–5.17) 0.111
A*30+Cw*03 42 20.3360.12 0.005 22 0.34 (0.13–0.88) 0.025
Association analyses begin with a typical, cross-sectional study design to emphasize statistical power (Series 1). In Series 2, subjects with mediumV L( 1 0
4–10
5 copies/
mL) are excluded, with the assumption that they may occasionally obscure the classification of patients with low and high VL (Table 1). For consistency, sex and age are
treated as covariates in each univariate analysis; statistically significant relationships (p,0.05) are shown in bold. CI = confidence interval; OR = odds ratio;
SE = standard error.
doi:10.1371/journal.pone.0009629.t002
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combination dominated the independent effects, with mean beta
estimates ranging from 20.47 to 20.92 log10 (,3.0- to 8.3-fold)
(p,0.05). These effects were ranked as B*13.B*57.A*74.
(A*30+Cw*03) or B*13.A*74.Cw*18.(A*30+Cw*03) when
B*57 was replaced Cw*18 in the reduced multivariable model.
The adjusted effect sizes attributed to all five favorable HLA
variants in aggregate exceeded the effect sizes for age and sex. In
contrast to the model for SPs, a model for SCs that included both
B*57 and Cw*18 indicated a non-significant association with
Cw*18 (data not shown).
In further assessment of favorable and unfavorable HLA
variants retained in the multivariable models (Table 5), it was
evident that they did not segregate by a) specific HLA-A and HLA-
B supertypes, including those that have been added or refined
recently [45], b) HLA serological groups (properties as alloanti-
Table 4. Quantitative impact of 14 HLA variants on log10 HIV-1 viral load in two groups of Zambians.
Tests in 563 seroprevalent Zambians (SPs) Tests in 221 seroconverters (SCs)
HLA variants No. of subjects b 6 SE
b p No. of subjects b 6 SE
b p
A*29 85 0.0760.09 0.392 26 20.4260.17 0.015
A*36 63 0.2960.10 0.004 32 0.2160.16 0.189
A*74 86 20.1560.09 0.086 22 20.5960.18 ,0.001
B*13 22 20.0360.16 0.860 6 20.7860.33 0.021
B*42 124 20.0160.08 0.905 35 20.1460.15 0.360
B*45 68 0.2560.09 0.010 38 20.0460.15 0.804
B*57 75 20.2860.09 0.002 18 20.6260.20 0.002
B*5802 36 0.2860.13 0.027 29 0.3360.16 0.045
B*8101 39 20.2760.12 0.025 13 20.2960.23 0.204
Cw*16 66 0.1660.10 0.096 34 0.0260.15 0.886
Cw*18 90 20.3960.08 ,0.0001 21 20.3060.19 0.113
DRB1*0102 39 0.3860.12 0.002 21 20.0260.19 0.894
A*23+Cw*07 41 0.2260.12 0.072 15 0.3160.22 0.165
A*30+Cw*03 29 20.3060.14 0.034 13 20.4560.25 0.071
HLA variants are the same as those presented in Table 3. The parameter estimates (mean beta and standard error, SE) are statistically adjusted for sex and age; numbers
in bold have adjusted p values#0.05.
doi:10.1371/journal.pone.0009629.t004
Table 3. Distribution of 14 HLA variants in HIV-1 seroprevalent and seroconverted Zambians stratified by three levels of plasma
viral load.
Distribution (n, %) in 563 seroprevalent Zambians (SPs) Distribution (n, %) in 221 seroconverters (SCs)
HLA variant ,10
4 (N=105)
10
4–10
5
(N=232) .10
5 (N=226) Ptrend
,10
4
(N=54) 10
4–10
5 (N=103) .10
5 (N=67) Ptrend
A*29 13 (12.4) 38 (16.4) 34 (15.0) 0.662 11 (21.6) 9 (8.7) 6 (9.0) 0.048
A*36 7 (6.7) 25 (10.8) 31 (13.7) 0.057 2 (3.9) 16 (15.5) 14 (20.9) 0.011
A*74 21 (20.0) 37 (16.0) 28 (12.4) 0.068 9 (17.7) 10 (9.7) 3 (4.5) 0.019
B*13 3 (2.9) 11 (4.7) 8 (3.5) 0.936 4 (7.8) 0 2 (3.0) 0.166
B*42 23 (21.9) 52 (22.4) 49 (21.7) 0.928 14 (27.5) 11 (10.7) 10 (14.9) 0.098
B*45 9 (8.6) 25 (10.8) 34 (15.0) 0.068 8 (15.7) 16 (15.5) 14 (20.9) 0.426
B*57 26 (24.8) 27 (11.6) 22 (9.7) ,0.001 7 (13.7) 11 (10.7) 0 0.005
B*5802 5 (4.8) 8 (3.5) 23 (10.2) 0.016 5 (9.8) 14 (13.6) 10 (14.9) 0.427
B*8101 11 (10.5) 16 (6.9) 12 (5.3) 0.096 6 (11.8) 1 (1.0) 6 (9.0) 0.711
Cw*16 10 (9.5) 21 (9.1) 35 (15.5) 0.054 6 (11.8) 13 (12.6) 15 (22.4) 0.094
Cw*18 31 (29.5) 36 (15.5) 23 (10.2) ,0.0001 8 (15.7) 8 (7.8) 5 (7.5) 0.154
DRB1*0102 2 (1.9) 14 (6.0) 23 (10.2) 0.004 5 (9.8) 8 (7.8) 8 (11.9) 0.641
A*23+Cw*07 5 (4.8) 15 (6.5) 21 (9.3) 0.113 2 (3.9) 8 (7.8) 5 (7.5) 0.481
A*30+Cw*03 7 (6.7) 15 (6.5) 7 (3.1) 0.106 6 (11.8) 5 (4.9) 2 (3.0) 0.052
HLA variants shown here have been confirmed in further analyses (generalized linear models, Table 4) or reported in earlier studies of native Africans with HIV-1C
infection [28,35,41,42].
doi:10.1371/journal.pone.0009629.t003
HLA and HIV-1 Viral Load
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homozygosity and heterozygosity within the study population.
Discussion
Our expanded analyses of VL as a quantitative trait (log10 copy
number) or as a categorical outcome measure in adult Zambians
confirmed most of the favorable and unfavorable HLA associa-
tions that we previously reported [28]; this study also yielded three
new, internally consistent findings. First, the associations of most of
the favorable HLA class I alleles were more readily detected in
seroconverters (SCs) than in seroprevalent subjects (SPs), even
though SPs outnumbered SCs by 2-fold. HLA-A*74, B*57 (or
Cw*18), and A*30+Cw*03 were clearly favorable; B*13 also
appeared favorable in the few SCs with this allele. For each of
these variants, its biologically and epidemiologically meaningful
impact on VL either substantially diminished or totally vanished in
SPs. Second, individual alleles and haplotypes at HLA class II loci
were not prominently associated with altered viremia at the
population level. Only one class II allele (DRB1*0102) was
associated with high VL, and only in SPs. No other HLA class II
allele or haplotype, including any previously reported to be
associated with HIV-1 transmission or acquisition [[28,35,41,42],
showed appreciable impact on VL in either patient group. Third,
an alternative study design that included only about 60% of the
population with the two extreme categories of VL yielded very
similar results (Table S2). In resource-limited settings that require
concentration on patients with extreme outcomes [26,43],
considerable savings in cost may be achieved with relatively little
loss of power, especially for exploratory studies of genetic
determinants.
Plasma VL during untreated, chronic HIV-1 infection reflects
an equilibrium between viral replication and immunologically
mediated viral clearance. Population-based studies have clearly
established the predictive value of VL for heterosexual HIV-1
transmission [31,46] as well as time to AIDS, especially in
Caucasian males [18,47,48]. Although our initial work indicated
that variants from all three HLA class I genes were associated with
VL in chronically infected Zambians [28], similar work based on a
South African cohort has shown that HLA-B allele played the most
dominant role [35]. In the same South African cohort, several
favorable HLA alleles (B*42, B*57, B*5801, and B*8101) were
further predictive of CD4
+ T-cell slope over a 2-year follow-up
period [42]. Our analyses here did not support the favorable
association of B*42, although A*29 as a marginally favorable allele
in Zambians (seroconverters only) showed weak LD with B*42.
Two other HLA-A alleles (A*36 as unfavorable and A*74 as
favorable) had even stronger associations, none of which could be
explained by effects of their accompanying HLA-B and HLA-C
alleles. Both alleles have been confirmed in recent analyses of
African-Americans (unpublished results, available from RAK and
JT). Thus, although the influences of multiple HLA-B variants on
HIV-1 pathogenesis and evolution have been more readily
detected and confirmed, several HLA-A alleles can exert
comparable effects.
HLA-B and HLA-C genes are located in a genomic segment (the
beta block) rarely disrupted by recombination hot spots
[49,50,51,52,53]. As a result, the associations of two HLA-C
alleles (Cw*16 as unfavorable and Cw*18 as favorable) with VL in
Zambians could be partially or completely explained by their
strong LD with HLA-B alleles: B*45 for Cw*16 and B*57 plus
B*8101 for Cw*18. However, as we noted earlier [30],
experimental evidence does suggest that Cw*1801 is able to
present viral epitopes for cytotoxic T-lymphocyte (CTL) responses,
which might account for its relatively durable impact on VL.
Identification of one favorable A-C combination (A*30+Cw*03)
further supported the role of HLA-C alleles in HIV-1 infection,
because none of these alleles individually had a clear association
with VL. Assuming that alleles at HLA-C and HLA-A can act in
concert to confer genetic advantage during HIV-1 infection (or
disadvantage in other settings), differences in peptide-binding and
in HLA-C allelic expression can offer two plausible explanations
[20,54]. Of note, environmental factors can further complicate the
genotype-phenotype relationships by influencing gene expression
in leukocytes [55].
HLA class II molecules specialize in presenting exogenous
antigens for immune surveillance by CD4
+ T-helper (TH) cells.
Their peptide-binding grooves can be loaded with protein
degradation products (13–25 amino-acid residues) generated in
the lysosome. CD4
+ T-cells that effectively respond to HIV-1
antigens can facilitate immune control through cytokines and T-
cell-dependent antibody responses, but activated TH cells,
especially those specific to HIV-1 antigens, are lost rapidly
because they are preferentially targeted by the virus [56]. Striking
Table 5. Multifactorial influences on log10 viral load (VL) in HIV-1 seroprevalent Zambians (SPs) and seroconverters (SCs).
Reduced model 1: 563 SPs Reduced model 2: 221 SCs
Covariates No. of subjects b 6 SE p No. of subjects b 6 SE p
Sex = F 275 20.5360.06 ,0.0001 131 20.4160.11 ,0.001
Age $40 yrs 108 20.0860.08 0.344 30 0.3660.15 0.020
A*36 63 0.2560.10 0.009
A*74 86 20.2060.08 0.017 22 20.5960.17 ,0.001
B*13 6 20.9260.32 0.004
B*57 75 20.3060.09 0.001 18 20.6060.19 0.002
B*8101 39 20.2860.12 0.019
Cw*18 90 20.3960.08 ,0.0001 21 20.3760.18 0.041
A*30+Cw*03 29 20.3260.14 0.020 13 20.4760.23 0.045
DRB1*0102 39 0.3860.12 0.002
The parameter estimates (mean beta and standard error, SE) are adjusted for all factors retained in each model. Because of strong LD (see text), B*57 and Cw*18 (in
bold) are entered into separate models for both SPs and SCs.
doi:10.1371/journal.pone.0009629.t005
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has identified 33 HIV-1 epitopes recognized by CD4
+ T-cells in
patients with chronic HIV-1C infection [57]. Direct interactions
between HIV-1 and HLA class II molecules have also been
reported [58,59,60,61]. Among individual HLA class II alleles,
DRB1*1301 has been seen as a favorable allele in various
populations [23,32,62]. Our analyses here failed to confirm any of
the previously reported HLA class II alleles or haplotypes. Instead,
DRB1*0102 was associated with higher VL, but only in SPs. The
relationship counters to the hypothesized early involvement of
class II molecules, before the precipitous loss of CD4
+ T-cells. The
largely inconclusive findings for HLA class II alleles and
haplotypes might reflect their promiscuity in antigen presentation.
Within the context of HIV-1C infection, the Zambian cohort has
produced some of the first evidence that HLA factors can mediate
HIV-1 VL as well as heterosexual transmission [28,30,32].
Identification of favorable HLA factors in this cohort is particularly
encouraging, as relatively few HLA alleles have unequivocal
(consensus) effects in various investigations, especially in the era of
highly active antiretroviral therapy [29]. For the few favorable HLA
class I alleles confirmed in the Zambian, several have known or
predicted HIV-1 epitopes [12,63,64]. For example, epitope-specific
functionalcorrelationiswelldocumented forB*57[44,65].B*13(all
B*1302 in Zambians) is another class I allele repeatedly observed as
favorable [7,42,66,67,68,69]. The impact of the favorable HLA
class I alleles and haplotypes on VL was consistently more
prominent in SCs than in SPs, suggesting that immune control
mediated by favorable alleles like B*57 and B*13 diminish with
time, most likely due to viral immune escape and accumulation of
compensatory mutations [11,12,70,71,72]. Further association of
favorable HLA alleles (B*57 and Cw*18) with reduced rates and
incidences of heterosexual HIV-1 transmission in the Zambian
cohort was also most apparent during the early follow-up period
[30]. Continuing efforts to monitor the evolution of viral epitopes
targeted by favorableHLAvariants should provide critical guidance
for HIV-1 vaccine design and clinical trials.
When expressed as a log10 value (a continuous variable), VL
differences greater than 0.30 log10 (,2-fold) are often considered
biologically and epidemiologically significant [19,33]. By our
analyses, at least four favorable HLA class I alleles and one
favorable combination independently conferred biologically and
epidemiologically important impact on VL in SCs (Table 5). By
contrast, the absence of advantageous class II variants highlights
the importance of CTL and likely natural killer (NK) cell activities
mediated by the three HLA class I genes. In particular, one or
both of these pathways must be effective in controlling HIV-1
infection, since VL set-point is typically reached within the first
nine weeks after HIV-1 infection [73], before the debut of high-
affinity neutralizing antibody responses [74,75]. Again, collection
of longitudinal VL and viral sequencing data from SCs will help
determine the timing and scope of viral immune escape, as already
reported for HIV-1 gag variants [13,44]. In addition, ongoing
elucidation of KIR genotypes should set the stage for thorough,
systematic evaluation of HLA-KIR interaction, which is the
second and potentially critical pathway by which HLA class I
alleles may regulate HIV-1 infection.
Materials and Methods
Ethics Statement
This study complied with the human experimentation guide-
lines of the United States Department of Health and Human
Services, and all enrolled patients provided written informed
consent. The work presented here was further approved by the
Institutional Review Boards at University of Alabama at Birming-
ham, under Protocols X051108005 and X071119002.
Study Population, HIV-1 Viral Load (VL), and HLA
Genotyping
Beginning in 1995, HIV-1 seropositive Zambians were recruited
and followed by the Rwanda/Zambia HIV-1 Research Group in
Lusaka, Zambia. Procedures for quarterly medical examination,
voluntary counseling and testing, and viral sequencing have been
described elsewhere [31,65,76,77,78]. Measurements of plasma
HIV-1 VL (RNA copies) were made in most cases with the Roche
Amplicor 1.0 assay (Roche Diagnostics Systems Inc., Branchburg,
NJ), which had a lower limit of detection (LLD) of 400 RNA copies
per ml of plasma. HLA genotyping relied on a combination of
PCR-based methods, including PCR with sequence-specific
primers (SSP) (Dynal/Invitrogen, Brown Deer, WI), automated
sequence-specific oligonucleotide (SSO) probe hybridization (In-
nogenetics, Alpharetta, GA), and sequencing-based typing (SBT)
(Abbott Molecular, Inc., Des Plaines, IL) using capillary
electrophoresis and the ABI 3130xl DNA Analyzer (Applied
Biosystems, Foster City, CA) [30,79]. HLA alleles were resolved to
the first four digits, which correspond to distinct protein products
designated by the World Health Organization Nomenclature
Committee for Factors of the HLA System [80,81].
Computational Assignment of Local and Extended HLA
Haplotypes
Using the expectation-maximization (EM) algorithm in SAS
Genetics (SAS Institute, Cary, NC), common HLA class I B-C
haplotypes were assigned for HLA-B and HLA-C alleles because of
their known, strong linkage disequilibrium (LD) in the study
population [30]. DRB1-DQB1 haplotypes were assigned for HLA-
DRB1 and HLA-DQB1 alleles in the same way and for the same
reason [32]. Assignments of these 2-locus (local) haplotypes helped
to distinguish allelic from haplotypic effects. Assignments of
extended haplotypes were assessed by relative LD (D’) and
correlation coefficients (r). In a given individual, simultaneous
assignments of two haplotypes with a statistical probability $70%
by the EM algorithm were considered reliable. Individuals with
unreliable haplotype assignments (probabilities ,70%) were
excluded from formal testing of haplotypic associations.
Descriptive Statistics
The overall characteristics of HIV-1 seroprevalent Zambians
(SPs) and seroconverters (SCs) with complete HLA genotyping were
summarizedinTable1.Differencesbetweenthetwopatient groups
were assessed using Mann-Whitney U test (fro duration of infection
orfollow-up),Student’st-test(forageandlog10viralload),andx
2test
(for sex ratio, age group, and three categories of viral load).
Analyses of HLA Variants in Relation to HIV-1 VL
The statistical approach to association analysis followed the
strategies established in other related work [28,30,31,82,83],
except that a) enlarged sample size (improved statistical power)
facilitated separate analyses of 563 SPs versus 221 SCs, b) 56
individuals (32 SPs and 24 SCs) representing couples with unlinked
viruses were retained in analyses because HLA genotyping had
already been completed before non-identity of the virus in
suspected recipients (seroconverters) was established; c) 19 SPs
from cohabiting couples with short (,9 mth) follow-up were also
included; d) 18 patients (15 SPs and 3 SCs) with VL less than the
lower limit of detection (400 copies/mL) were excluded; e) several
univariate models were presented in order to facilitate meta-
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(SAS Institute), and g) results sorted in SAS were used to produce
graphs using GraphPad Prism version 5.0 (http://www.graphpad.
com/prism/Prism.htm). Summary statistics in association analyses
included: 1) proportional odds ratio (pOR) and 95% confidence
intervals (CIs); 2) regression beta estimates, expressed as means
and standard errors (SE), and 3) univariate and multivariable
(adjusted) p values. A p value#0.050 was considered statistically
significant because most HLA alleles and haplotypes highlighted in
this work have been implicated in earlier studies. The overall
emphasis was on biologically and epidemiologically significant
(.0.30 log10) differences in VL [19,33].
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